A venture studio and investment firm based in Asia currently manages a portfolio with half of the companies from their country of origin, and the half from across the globe (mostly USA, but some in Europe and Asia). The firm invests primarily in Seed to Pre-Series A rounds and focuses on life science and healthcare investments, with typical check sizes around $1-2M. The firm actively seeks global opportunities.
The firm is agnostic towards sectors and indication areas. The firm has invested across all life science sectors, with a diverse portfolio in therapeutics, medical devices, diagnostics, and digital health. As an early-stage focused investor, the firm welcomes projects that are as early as idea or conception stage, and is open to pre-clinical stage companies.
Previously, the firm had a focus on oncology, infectious disease, cardiovascular disease, and CNS. Regarding diagnostics, the firm had an additional focus on -omics and AI-based diagnostics, as well as infectious disease point-of-care diagnostics. For digital health, the firm is interested in precision medicine drug discovery, wearable sensors, digital therapeutics, home healthcare, and hospital tools.
Though the firm does not have specific areas of interest and has broad interests in life sciences, the firm prioritizes areas with truly unmet need where there has not been enough advancements in delivering a therapeutic solution, and looks for novel technologies that have the potential to address a wide market. To date, the firm has not led investment rounds, but is open to co-leading in the future.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment